You have the key to Unlock it

For Your Cancer Patients In Advanced Stage

Please apply the key to unlock life

 Feedback on usage of Bevacizumab for various indications

Colorectal Ovarian Cervical

NSCLC GBM RCC
Cancer Cancer Cancer
 Feedback on usage of Bevacizumab for various indications

Cervical NSCLC Ovarian Colorectal

GBM RCC
Cancer Cancer Cancer Cancer

5% 5% 5% 5% 5% 5%
10% 10% 10% 10% 10% 10%
15% 15% 15% 15% 15% 15%
20% 20% 20% 20% 20% 20%
25% 25% 25% 25% 25% 25%
30% 30% 30% 30% 30% 30%
35% 35% 35% 35% 35% 35%
40% 40% 40% 40% 40% 40%
45% 45% 45% 45% 45% 45%
50% 50% 50% 50% 50% 50%
55% 55% 55% 55% 55% 55%
60% 60% 60% 60% 60% 60%
65% 65% 65% 65% 65% 65%
70% 70% 70% 70% 70% 70%
75% 75% 75% 75% 75% 75%
80% 80% 80% 80% 80% 80%
85% 85% 85% 85% 85% 85%
90% 90% 90% 90% 90% 90%
95% 95% 95% 95% 95% 95%
100% 100% 100% 100% 100% 100%

Colorectal Ovarian Cervical

NSCLC GBM RCC
Cancer Cancer Cancer
COLORECTAL
CANCER
40%

OVARIAN
CANCER
25%

CERVICAL
CANCER
15%
NSCLC
8%
GBM
5%
RCC
5%
In metastatic Colorectal Cancer

Establish Overall Survival as First line irrespective of

Improve overall survival in
Metastatic Colorectal Cancer

Increase median Overall Survival by 4.7 months in first line mCRC

Median OS:
25 20.3
20.3
20 15.6
vs
OS (Months)

15 15.6
10
months
(HR=0.66 [95% CI,
05
0.54-0.81], P<0.001)

0 Bevacizumab + IFL Placebo + IFL

(n=402) (n=411)

ABBREVIATION
Improve overall survival in
Metastatic Colorectal Cancer

Increase median Overall Survival by 2.2 months in first line mCRC

Median OS:
25
13.0
20
vs
OS (Months)

13.0
15
10.8
10.8
10
months
(HR=0.75 [95% CI,
05
0.63-0.89], P=0.001)
0 Bevacizumab + FOLFOX4 FOLFOX4 alone
(n=286) (n=291)

ABBREVIATION
ABBREVIATION
Improve overall survival in platinum sensitive
recurrent epithelial ovarian Cancer

Significantly increase median Overall Survival by 5.3 months

Median OS:
50
42.6 42.6
40
37.3 vs
OS (Months)

37.3
30
months
20 (HR=0.84 [95% Cl,
0.69-1.01] [IVRS])
10 (HR=0.82 [95%
Cl,0.68-0.996] [eCRF])
0 Bevacizumab + chemotherapy Chemotherapy alone
(n=337) (n=336)

ABBREVIATION
Improve Overall survival in persistent,
recurrent or metastatic Cervical Cancer

Significantly increase median Overall Survival by 3.9 months

Median OS:
25
16.8
20 16.8 VS
OS (Months)

15
12.9
12.9
months
10 (HR=0.74 [95% Cl,

05 0.58-0.94], p=0.0132)

0 Bevacizumab + chemotherapy Chemotherapy alone

(n=227) (n=225)

ABBREVIATION